کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5902416 1156851 2015 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study
ترجمه فارسی عنوان
ایمنی قلبی عروقی ترشح انسولین پس از بستری شدن در بیماران مبتلا به بیماری قلبی ایسکمیک در بیماران دیابتی نوع 2: مطالعه کوهورت
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی علوم غدد
چکیده انگلیسی

AimTo evaluate the association between insulin secretagogues and adverse cardiovascular sequelae in type 2 diabetes patients hospitalized for ischemic heart disease (IHD).MethodsAdministrative health records from Alberta, Canada between 1998 and 2010 were used to identify 2,254 gliclazide, 3,289 glyburide and 740 repaglinide users prior to an IHD-related hospitalization. Multivariable Cox regression models were used to compare the 30-day risk of a composite outcome of all-cause mortality or new onset of atrial fibrillation, stroke, heart failure or myocardial infarction according to insulin secretagogue use.ResultsMean (SD) age was 76.1 (6.9) years, and 60.7% were men. The composite outcome occurred in 322 (30.2%) gliclazide users, 455 (28.1%) glyburide users and 81 (23.4%) repaglinide users within 30 days of IHD hospitalization. There were no differences in risk for glyburide use (adjusted hazard ratio [aHR] 0.91; 95% confidence interval [CI] 0.78-1.05) or repaglinide use (aHR 0.80; 95% CI 0.63-1.03) compared to gliclazide. Similar results were observed in analyses for each element of the composite outcome.ConclusionsIn older patients with type 2 diabetes hospitalized for IHD, prior use of gliclazide, glyburide, or repaglinide appears to be associated with a similar risk of adverse cardiovascular sequelae.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Diabetes and its Complications - Volume 29, Issue 2, March 2015, Pages 196-202
نویسندگان
, , , , ,